
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 09, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Erlotinib Tablets, 25 mg, 100 mg, and 150 mg".
Filed with NSE ·

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 09, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Erlotinib Tablets, 25 mg, 100 mg, and 150 mg".
6ix hasn’t read this filing yet.
Alembic Pharmaceuticals Limited on 6ix
Follow Alembic Pharmaceuticals into a list and get an email when it puts out news.
Follow Alembic Pharmaceuticals